Collegium Pharmaceutical (COLL) Competitors $35.62 +0.70 (+2.00%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$35.62 0.00 (0.00%) As of 09/16/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, and MLTXShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Its Competitors PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics PTC Therapeutics (NASDAQ:PTCT) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Which has stronger earnings and valuation, PTCT or COLL? Collegium Pharmaceutical has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M5.88-$363.30M$6.978.56Collegium Pharmaceutical$631.45M1.78$69.19M$1.0434.25 Is PTCT or COLL more profitable? PTC Therapeutics has a net margin of 35.65% compared to Collegium Pharmaceutical's net margin of 5.13%. Collegium Pharmaceutical's return on equity of 97.28% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Collegium Pharmaceutical 5.13%97.28%13.87% Which has more volatility & risk, PTCT or COLL? PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Does the media prefer PTCT or COLL? In the previous week, PTC Therapeutics had 14 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 20 mentions for PTC Therapeutics and 6 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.12 beat PTC Therapeutics' score of 0.81 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PTCT or COLL? PTC Therapeutics currently has a consensus target price of $69.00, suggesting a potential upside of 15.60%. Collegium Pharmaceutical has a consensus target price of $42.33, suggesting a potential upside of 18.85%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryCollegium Pharmaceutical beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks. Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10B$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio34.2523.4975.8626.51Price / Sales1.78672.77528.72123.58Price / Cash2.83169.4937.1760.46Price / Book5.025.3312.796.29Net Income$69.19M$32.95M$3.28B$270.51M7 Day Performance-5.54%0.10%0.81%1.95%1 Month Performance-5.62%3.91%4.60%6.33%1 Year Performance-4.71%-3.91%70.39%25.62% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical3.9614 of 5 stars$35.62+2.0%$42.33+18.8%-4.0%$1.10B$631.45M34.25210Positive NewsPTCTPTC Therapeutics3.7179 of 5 stars$56.95-0.5%$69.00+21.2%+76.8%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9509 of 5 stars$145.20-3.4%$210.38+44.9%-20.5%$4.35B$290.52M29.51210Positive NewsAnalyst ForecastPCVXVaxcyte2.1741 of 5 stars$32.41-1.8%$130.00+301.1%-72.7%$4.29BN/A-7.89160Positive NewsACADACADIA Pharmaceuticals4.3265 of 5 stars$25.39+0.5%$28.88+13.7%+48.5%$4.26B$957.80M19.09510ACLXArcellx2.0899 of 5 stars$71.11-2.1%$114.31+60.7%+0.4%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.6473 of 5 stars$16.42-2.7%$27.67+68.5%-13.8%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1332 of 5 stars$27.17-6.6%$43.14+58.8%+43.9%$4.02B$3.55M-21.23400Insider TradeMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageGap UpHigh Trading VolumeMIRMMirum Pharmaceuticals3.3294 of 5 stars$77.39+1.7%$74.13-4.2%+82.6%$3.82B$336.89M-63.96140Positive NewsMLTXMoonLake Immunotherapeutics2.4965 of 5 stars$61.12+2.8%$74.43+21.8%+6.6%$3.82BN/A-21.992 Related Companies and Tools Related Companies PTCT Competitors KRYS Competitors PCVX Competitors ACAD Competitors ACLX Competitors ADMA Competitors ARWR Competitors MENS Competitors MIRM Competitors MLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
